facebook tracking
knowledge-service-img

Regulation/Guidelines

Post-Market Surveillance for Cosmetics in India: What CDSCO Expects After Launch

Getting a Cosmetic product registered and onto shelves in India is only half the job. Once a product is in the market, the Cosmetics Rules, 2020 place ongoing duties on manufacturers and Importers to keep watching it. This is called post-market surveillance, and it is becoming one of the areas […]

Read More

Regulation/Guidelines

AI in Regulatory Affairs and Clinical Development: What Pharmaceutical Companies Need to Know in 2026 

Artificial intelligence is reshaping Pharmaceutical research and development, regulatory affairs, and clinical operations at a pace that few industries have previously experienced. From AI-accelerated drug discovery and predictive Clinical Trial design to AI-enabled regulatory dossier review and real-time pharmacovigilance signal detection, the technology is moving from experimental adoption into mainstream […]

Read More

Regulation/Guidelines

India as a Cosmetic Manufacturing Hub: CDSCO, BIS, and the Regulatory Enablers for Global Manufacturers 

The Strategic Shift  For most global Cosmetic brands, India’s regulatory journey has begun with import registration — the COS-2 pathway explored throughout this series. But for a growing cohort of global Manufacturers, India is no longer purely an import destination. It is a manufacturing location, an export base, and increasingly, […]

Read More
knowledge-service-img

Regulation/Guidelines

Software as a Medical Device (SaMD) – India’s Regulatory Stance  

Although software intended for Medical purposes has been regulated in India since the implementation of MDR, 2017 Rules. CDSCO’s Guidance Document on Medical Device Software (Doc No. CDSCO/MD/GD/MDSW/01/2026), issued on 21 July 2026, represents the first comprehensive regulatory guidance dedicated specifically to software-based medical technologies. Through Circular F. No. MED-16028/2/2025-office, […]

Read More
knowledge-service-img

Regulation/Guidelines

Post-Market Surveillance Under Medical Device Rules, 2017  

Regulatory approval is often treated as the finish line. In reality, for Medical Device and IVD manufacturers in India, it marks the start of an equally demanding obligation: Post-Market Surveillance (PMS). Under the Medical Device Rules, 2017, “Post-Marketing Surveillance” means a systematic process to collect and analyse information gained from […]

Read More
knowledge-service-img

Regulation/Guidelines

How to Sequence Global and India Market Entry for Medical Devices Without Creating Regulatory Rework

One of the most avoidable and expensive mistakes in Medical Device commercialisation is Regulatory rework — the process of going back to redo documentation, testing, or submissions  because the original data was not designed to serve multiple regulatory frameworks. Companies that plan their global market entry sequence intelligently can avoid […]

Read More

Regulation/Guidelines

The Future of Biological Regulation in India: Biosimilars, CAR-T, AI & Advanced Therapies

India’s Biological Regulatory landscape is at an inflection point. The country that pioneered affordable Biosimilar access, built one of the world’s largest vaccine manufacturing ecosystems, and established the framework for recombinant Biological oversight is now navigating a new wave of regulatory complexity — driven by CAR-T cell therapies, personalised medicine, […]

Regulation/Guidelines

Recall Management for Medical Devices in India

A Recall is one of the few regulatory events where speed of response directly influences both patient safety outcomes and a company’s regulatory standing. Yet many manufacturers only consider their Recall process after a Recall becomes necessary — by which point, the absence of a pre-built protocol costs valuable time, […]

Regulation/Guidelines

How to Build an Indian Regulatory Strategy for Advanced Biologicals Before Entering the Market 

The decision to enter the Indian market with an advanced Biological product should be made with a comprehensive regulatory strategy in place. India’s multi-authority regulatory environment, distinct clinical data requirements, unique quality expectations and complex commercial landscape reward companies that invest in strategic regulatory planning before beginning product development or […]